HC Wainwright Reaffirms “Buy” Rating for Repare Therapeutics (NASDAQ:RPTX)

HC Wainwright restated their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $10.00 price target on the stock.

Separately, Lifesci Capital upgraded Repare Therapeutics to a strong-buy rating in a report on Monday, July 29th.

Repare Therapeutics Trading Up 3.6 %

Repare Therapeutics stock opened at $3.50 on Monday. The company has a market capitalization of $148.58 million, a P/E ratio of -3.18 and a beta of 0.71. Repare Therapeutics has a 1-year low of $2.71 and a 1-year high of $12.77. The firm’s fifty day simple moving average is $3.24 and its 200-day simple moving average is $3.59.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.03. The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. On average, equities research analysts predict that Repare Therapeutics will post -2.15 earnings per share for the current year.

Institutional Investors Weigh In On Repare Therapeutics

A number of hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in shares of Repare Therapeutics during the 2nd quarter worth about $110,000. Jump Financial LLC bought a new position in Repare Therapeutics in the 4th quarter worth approximately $289,000. Opaleye Management Inc. acquired a new position in shares of Repare Therapeutics during the first quarter worth approximately $318,000. Marshall Wace LLP bought a new stake in shares of Repare Therapeutics in the second quarter valued at approximately $273,000. Finally, Bank of Montreal Can grew its stake in shares of Repare Therapeutics by 5.4% in the second quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock worth $366,000 after acquiring an additional 5,673 shares during the last quarter. 85.09% of the stock is currently owned by institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.